A
0.853
-0.02 (-2.40%)
AIStockmoo Score
| Value 30% | -1.7 |
| Weak profitability. Ample short-term liquidity. Negative cash flow. info | |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| Implied Growth info | NA |
| Valuation History info | NA |
| Return on Capital info | NA |
| Holdings' Value info | NA |
| Risk Premium info | NA |
| Market Valuation info | NA |
| Timing 30% | -4.5 |
| Downtrend over the past year. Far below its 52-week high. info | |
| In a downtrend: the price is below its moving averages, and they are falling. It is close to them. Volume is heavier on down days. info | |
| From our AI technical analysis of the chart. info | NA |
| Candle Patterns info | NA |
| Sentiment 20% | 0.0 |
| No recent price targets, so based on how targets have been revised. info | |
| Holdings' Sentiment info | NA |
| News Mood info | NA |
| Smart Money 20% | 3.0 |
| Insiders net buying recently. info | |
| Institutional Flow info | NA |
| Market and sector conditions are poor. | |
| Market environment cautious. info | |
| Sector lagging the market. | |
| The pillars agree, so the score is strengthened. | |
| Not in score | |
| Below its medium-term trend line. info | |
| Price is low against its 52-week average. Down over 5 years. info | |
| Short-term momentum falling. info | |
| Price is near support. info | |
| Final Score | -1.42 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Annovis Bio, Inc. | Mixed | Mixed |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B | Score |
|---|---|---|---|---|---|
| ANVS | - | - | - | 16.34 | -1.4 |
| ADCT | - | - | - | - | -1.3 |
| DNA | - | - | - | 1.68 | 1.2 |
| ANRO | - | - | - | 4.13 | 0.0 |
| RCUS | - | - | - | 6.21 | -1.8 |
| NUVB | - | - | - | 6.18 | -1.1 |
Select this tab to load the latest available analysis.
|
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 14.69% |
| % Held by Institutions | 16.09% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Empery Asset Management, Lp | 30 Jun 2026 | 2,401,476 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HOFFMAN MICHAEL B | 0.840 | - | 5,000,000 | 4,200,000 |
| Aggregate Net Quantity | 5,000,000 | |||
| Aggregate Net Value ($) | 4,200,000 | |||
| Aggregate Avg. Buy ($) | 0.840 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| HOFFMAN MICHAEL B | Director | 06 Nov 2026 | Buy (+) | 5,000,000 | 0.840 | 4,200,000 |
0 Positive
0 Negative
2 Neutral
| Date | Type | Details |
|---|---|---|
| 09 Nov 2026 | Yahoo Finance |
Annovis Announces Closing of $21.0 Million Public Offering with 24% Contribution from the Board Chairman
Annovis Chairman of the Board invested $5.0 million as part of the underwritten public offering Company expects cash to fund operations through the pivotal Phase 3 Alzheimer’s data readout in March 2027 MALVERN, Pa., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the… |
| 04 Nov 2026 | Yahoo Finance |
Annovis Announces Launch of Proposed Public Offering
MALVERN, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s… |
| 30 Oct 2026 | Yahoo Finance |
Annovis Bio, Inc. Receives Continued Listing Standard Notice from the NYSE
MALVERN, Pa., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's… |
| 29 Oct 2026 | Yahoo Finance |
Annovis to Participate in U.S. Biotech Day 2026 and Pharma Partnering Summit 2026
Maria Maccecchini, PhD, CEO of Annovis, will join industry panel with pharma leaders and present company updatesMALVERN, Pa., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational… |
| 22 Oct 2026 | Yahoo Finance |
Annovis to Attend the CTAD 2026 with Three Presentations
MALVERN, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s… |
| 06 Oct 2026 | Yahoo Finance |
Parkinson's Disease Market Poised for Expansion During the Forecast Period (2026-2036) Amid JUVMO Approval and Emerging Therapeutic Innovations | DelveInsight
Recently published Parkinson's Disease Market Insights report includes a comprehensive understanding of current treatment practices, Parkinson's disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets… |
| 23 Sep 2026 | Yahoo Finance |
Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer’s Disease
MALVERN, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s… |
| 08 Sep 2026 | Yahoo Finance |
Annovis Bio (ANVS) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Annovis Bio (ANVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
| 02 Sep 2026 | Yahoo Finance |
Annovis Bio Targets March 2027 Alzheimer’s Readout, Prepares Rolling NDA
Annovis Bio (NYSE:ANVS) said it expects to report top-line results from the six-month portion of its pivotal Phase III Alzheimer’s disease trial in March 2027, while preparing a rolling new drug application, or NDA, that management said could begin in May if the study meets its efficacy requirements… |
| 25 Aug 2026 | Yahoo Finance |
Annovis to Host Corporate Update Webinar on September 2, 2026
MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s… |
Technical Setup Medium
Trend order
Slope
Entry
Volume
In a downtrend: the price is below its moving averages, and they are falling. It is close to them. Volume is heavier on down days.
Nearest support: 0.586 – 0.655 · moderate level
Nearest resistance: 0.896 – 1.085 · strong level · tested often, may give way
AI Technical Analysis
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |